- Home
- AGIO
as 03-28-2025 2:30pm EST
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.
| Founded: | 2007 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 2.0B | IPO Year: | 2013 |
| Target Price: | $56.57 | AVG Volume (30 days): | 648.3K |
| Analyst Decision: | Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 11.64 | EPS Growth: | N/A |
| 52 Week Low/High: | $27.14 - $62.58 | Next Earning Date: | 05-01-2025 |
| Revenue: | $36,498,000 | Revenue Growth: | 36.07% |
| Revenue Growth (this year): | 50.61% | Revenue Growth (next year): | 223.79% |
Stock Insider Trading Activity of Agios Pharmaceuticals Inc. (AGIO)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Washburn Theodore James Jr. | AGIO | Principal Accounting Officer | Mar 1 '25 | Sell | $35.54 | 1,655 | $58,818.70 | 7,691 | |
| Gheuens Sarah | AGIO | Chief Medical Officer | Mar 1 '25 | Sell | $35.54 | 4,005 | $142,337.70 | 47,098 | |
| Goff Brian | AGIO | Chief Executive Officer | Mar 1 '25 | Sell | $35.54 | 12,947 | $460,136.38 | 83,139 | |
| Burns James William | AGIO | Chief Legal Officer | Mar 1 '25 | Sell | $35.54 | 4,005 | $142,337.70 | 18,650 | |
| Milanova Tsveta | AGIO | Chief Commercial Officer | Mar 1 '25 | Sell | $35.54 | 1,681 | $59,742.74 | 22,892 | |
| Jones Cecilia | AGIO | Chief Financial Officer | Mar 1 '25 | Sell | $35.54 | 2,275 | $80,853.50 | 25,829 | |
| Washburn Theodore James Jr. | AGIO | Principal Accounting Officer | Feb 1 '25 | Sell | $34.39 | 2,272 | $78,134.08 | 7,691 | |
| Milanova Tsveta | AGIO | Chief Commercial Officer | Jan 3 '25 | Sell | $32.18 | 2,804 | $90,232.72 | 22,892 |
Latest Agios Pharmaceuticals Inc. News
AGIO Breaking Stock News: Dive into AGIO Ticker-Specific Updates for Smart Investing
Zacks
a day ago
Wave Life Sciences (WVE) Stock Jumps 6.1%: Will It Continue to Soar?
Insider Monkey
2 days ago
Is Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) the Best Small Cap Stock to Buy Before They Explode?
GlobeNewswire
23 days ago
Agios Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Corporate Development & Strategy Officer
GlobeNewswire
24 days ago
Agios to Present at Upcoming Investor Conferences
Insider Monkey
a month ago
Is Agios Pharmaceuticals, Inc. (AGIO) the Best Small-Cap Stock to Buy Now?
GlobeNewswire
a month ago
Agios to Present at the TD Cowen 45th Annual Healthcare Conference on March 3, 2025
TipRanks
a month ago
Agios Pharmaceuticals price target lowered to $74 from $75 at Scotiabank
Zacks
a month ago
Agios' Q4 Loss Wider Than Expected, Pyrukynd Drives Revenues
Compare AGIO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "AGIO Agios Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.